Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2020

View Archived Issues

CanSino initiates phase I study of three-component DTcP vaccine candidate

BeiGene opens enrollment in phase I/II study of BGB-10188 for B-cell malignancies and solid tumors

Tonix and University of Alberta collaborate to develop novel COVID-19 vaccines

Winter depression-like behavior is regulated by seasonal changes in the NRF2 pathway

Targeted disruption of aquaporin-1 reduces intraocular pressure: potential gene therapy for glaucoma

Inhibition of P2X7 receptors improves synaptic and behavioral deficits in a Rett syndrome model

Oxidative DNA damage mediates colitis-associated colorectal cancer

New MVP against SVMP

Cynata receives ethics approval for MEND study of Cymerus MSCs in COVID-19

FDA approves IND for phase IIa study of opaganib for COVID-19

FDA clears IND application for phase II study of PLX cells in severe COVID-19

Health Canada grants approval for phase II study of LSALT peptide in patients with COVID-19

SNYE1 mutations associated with cerebellar ataxia and generalized dystonia

First-in-human results presented for SLC-0111 in advanced solid tumors

Cell competition links hyperinsulinemia to cancer

Boehringer Ingelheim identifies new NR2B receptor negative allosteric modulators

New phase I trial evaluates gene therapy to treat severe hemophilia A

New MAP3K5 inhibitors discovered at CJ HealthCare

Shanghai GeneChem synthesizes anti-CLDN128.2 antibodies

Shanghai Yichen Biomed patents EGFR-PD-1 bispecific antibodies

Roche describes new hepatitis B virus cccDNA formation inhibitors

Seattle Genetics initiates phase I study of SGN-TGT in advanced solid tumors and lymphomas

ZFYVE21 is a potential therapeutic target in cardiac allograft vasculopathy

FDA and China NMPA clear IND for Mabspace's humanized Claudin18.2 monoclonal antibody

SCN10A gene loss-of-function variant linked to neuropathy

FDA approves Retevmo for advanced RET-driven lung and thyroid cancers

Oncoinvent recruits for phase I study of Radspherin

FDA approves Lynparza with bevacizumab for HRD-positive advanced ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...